Keywords: اومالیزوماب; Food allergy; Food immunotherapy; Desensitization; Tolerance; Omalizumab;
مقالات ISI اومالیزوماب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: اومالیزوماب; Urticaria; Omalizumab; Mast cell; Clinical trials;
Keywords: اومالیزوماب; Asma; Omalizumab; Anti IgEAsthma; Omalizumab; Anti IgE
Keywords: اومالیزوماب; Uncontrolled severe allergic asthma; Anti-IgE; Omalizumab; Effectiveness; Observational study;
Keywords: اومالیزوماب; Chronic urticaria; Omalizumab; Anti-immunoglobulin E; TreatmentUrticaria crónica; Omalizumab; Anti-inmunoglobulina E; Tratamiento
Keywords: اومالیزوماب; Immunotherapy; allergy; asthma; omalizumab; allergens; recombinant; peptide; epicutaneous; intraepithelial; sublingual immunotherapy; AIT; Allergen immunotherapy; ILIT; Intralymphatic immunotherapy; MATA; Modified allergen tyrosine absorbate; MPL; Monopho
Keywords: اومالیزوماب; Asthma control; Omalizumab; Quality of life; Safety; Severe asthma;
Keywords: اومالیزوماب; Severe asthma; Galectin-3; Omalizumab; Proteomics analysis; Interactome;
Keywords: اومالیزوماب; Omalizumab; Anti-IgE; Rhinosinusitis; Rhinitis; Meta-analysis; AE; Adverse event; AR; Allergic rhinitis; DNSMS; Daily nasal symptom medication score; DNSSS; Daily nasal symptom severity score; DUAL; Depigoid und OmalizUmab bei Asthma SaisonaL Study; ITNG;
Keywords: اومالیزوماب; asthma; decision-analytic model; economic evaluation; omalizumab;
Keywords: اومالیزوماب; Chronic urticaria; Therapy; Antihistamines; Corticosteroids; Ciclosporin; Omalizumab;
Keywords: اومالیزوماب; Allergic asthma; Anti-IgE; Exacerbations; Omalizumab; ATE; Arterial thromboembolic event; ED; Emergency department; EXCELS; The Epidemiologic Study of Xolair (omalizumab); FDA; US Food and Drug Administration; FeNO; Fraction of exhaled nitric oxide; GETE;
Keywords: اومالیزوماب; Omalizumab; anti-IgE; local IgE; nasal polyposis; asthma; quality of life; AQLQ; Asthma Quality of Life Questionnaire; CRSwNP; Chronic rhinosinusitis with nasal polyposis; CT; Computed tomography; RSOM-31; 31-Item Rhinosinusitis Outcome Measuring Instrume
Keywords: اومالیزوماب; Allergic asthma; Omalizumab; Observational study; IgE; Medications; Moderate-to-severe asthma;
Keywords: اومالیزوماب; Chronic idiopathic urticaria; chronic spontaneous urticaria; H1-antihistamine; H2-antihistamines; hive; itch; leukotriene receptor antagonist; omalizumab; pruritus; wheal; AE; Adverse event; CIU/CSU; Chronic idiopathic urticaria/chronic spontaneous urtica
Keywords: اومالیزوماب; Airway remodeling; asthma; asthma control; asthma exacerbations; asthma impairment; asthma risk; asthma severity; early intervention in asthma; biomarkers; environment; genetics; inhaled corticosteroids; leukotriene receptor antagonists; long-acting β-ad
Keywords: اومالیزوماب; Allergic bronchopulmonary aspergillosis; IgE; Omalizumab; Prednisolone; Severe asthma
Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab
Keywords: اومالیزوماب; Omalizumab; Asthma; IgE; CXCL10; IL-12;
Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis
Keywords: اومالیزوماب; Chronic spontaneous urticaria; LASSO model; Urticaria activity score; Chronic urticaria; Symptom return; Omalizumab; Treatment discontinuation; AAC; Area above the curve; AUC; Area under the curve; BOCF; Baseline observation carried forward; CSU; Chronic
Chronic inducible urticaria: AÂ systematic review of treatment options
Keywords: اومالیزوماب; Urticaria; angioedema; inducible urticaria; omalizumab; antihistamines; review; AE; Adverse event; CindU; Chronic inducible urticaria; CSU; Chronic spontaneous urticaria; H1-AH; H1-antihistamine; ITT; Intention to treat; MD; Mean difference; RR; Risk rati
Response to omalizumab in patients with severe allergic asthma: A real-life study
Keywords: اومالیزوماب; Omalizumab; Asthma; GETE; Eosinophil count;
Efficacy of omalizumab treatment for patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in Taiwan
Keywords: اومالیزوماب; Chronic spontaneous urticaria; Efficacy; Maintenance treatment; Omalizumab; Safety;
Exposition ou exclusion allergénique dans l'allergie alimentaire sévère : prise en charge et immunothérapie dans cette population
Keywords: اومالیزوماب; Allergie alimentaire; Test de provocation par voie orale; Immunothérapie; Ãducation; Omalizumab; Régime; Food hypersensitivity; Food challenge; Immunotherapy; Education; Omalizumab; Diet;
Efficacy of long-term omalizumab therapy in patients with severe asthma
Keywords: اومالیزوماب; ACT; AHQ; Anti-IgE antibody; Omalizumab; Severe asthma;
Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease
Keywords: اومالیزوماب; Immunoglobulin; IgE; half-life; metabolism; omalizumab; FcRn; Neonatal Fc receptor; Gal; Galectin; PK; Prausnitz-Küstner;
Oral immunotherapy for food allergy: A Spanish guideline. Egg and milk immunotherapy Spanish guide (ITEMS GUIDE). Part 2: Maintenance phase of cow milk (CM) and egg oral immunotherapy (OIT), special treatment dosing schedules. Models of dosing schedules o
Keywords: اومالیزوماب; Guide; Oral immunotherapy; Desensitization; Specific oral tolerance induction; Milk allergy; Egg allergy; Omalizumab; Sublingual immunotherapy;
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma
Keywords: اومالیزوماب; Adverse event; arterial thromboembolic event; clinical trials; moderate to severe asthma; omalizumab; safety; serious adverse event; ATE; Arterial thromboembolic event; CBV; Cerebrovascular; CV; Cardiovascular; EXCELS; Epidemiologic Study of Xolair (Omali
Omalizumab Treatment Response in a Population With Severe Allergic Asthma and Overlapping COPD
Keywords: اومالیزوماب; asthma; COPD; omalizumab; respiratory care; targeted therapy; ACQ-5; Asthma Control Questionnaire; AQLQ; Asthma Quality of Life Questionnaire; AXR; Australian Xolair Registry; BD; bronchodilator; GINA; Global Initiative for Asthma; ICS; inhaled corticoste
Pacjentka z ciÄżkÄ
astmÄ
wyÅÄ
czona z leczenia omalizumabem po 12 tygodniach
Keywords: اومالیزوماب; ciÄżka astma; omalizumab; zaostrzenia; ciÄ
ża; Severe asthma; Omalizumab; Exacerbations; Pregnancy;
Skuteczne leczenia omalizumabem chorej na ciÄżkÄ
astmÄ alergicznÄ
z utrzymujÄ
cÄ
siÄ ÅagodnÄ
eozynofiliÄ
krwi obwodowej
Keywords: اومالیزوماب; astma; Åagodna eozynofilia; omalizumab; Asthma; Mild eosinophilia; Omalizumab;
Immunothérapie spécifique sous omalizumab en situation de maladie allergique respiratoire sévère. Quel impact ?
Keywords: اومالیزوماب; Immunothérapie spécifique; Omalizumab; Polysensibilisation; Maladie allergique sévère; Enfant; Allergen-specific immunotherapy; Omalizumab; Polysensitization; Severe allergic disease; Case report;
Effects of omalizumab in severe asthmatics across ages: A real life Italian experience
Keywords: اومالیزوماب; Omalizumab; Severe asthma; Elderly; Real-life; Age effect;
Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansion
Keywords: اومالیزوماب; Allergic asthma; Anti-immunoglobulin E; Dosing table; Modeling and simulation; Omalizumab;
Omalizumab for the treatment of chronic spontaneous urticaria: AÂ meta-analysis of randomized clinical trials
Keywords: اومالیزوماب; Omalizumab; meta-analysis; CSU; weekly itch score; weekly wheal score; adverse event; AE; Adverse event; CSU; Chronic spontaneous urticaria; RCT; Randomized, placebo-controlled trial; RR; Relative risk; UAS7; Urticaria activity score 7; WIS; Weekly itch s
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy
Keywords: اومالیزوماب; Milk allergy; oral immunotherapy; omalizumab; desensitization; sustained unresponsiveness; double-blind; placebo-controlled trial; dose-related adverse reactions; APC; Antigen-presenting cell; CMA; Cow's milk allergy; MOIT; Milk oral immunotherapy; OFC; O
The Use of Anti-IgE Therapy Beyond Allergic Asthma
Keywords: اومالیزوماب; Omalizumab; Urticaria; Asthma; Rhinitis; Atopic; ABPA; Allergic bronchopulmonary aspergillosis; CSU; chronic spontaneous urticaria; FcεRI; High-affinity IgE receptor; SCIT; Subcutaneous immunotherapy;
Asthma and lower airway diseaseThe Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy
Keywords: اومالیزوماب; Omalizumab; pregnancy; moderate-to-severe persistent allergic asthma; HCP; Health care provider; ICS; Inhaled corticosteroids; LABA; Long-acting β2-agonist; MACDP; Metropolitan Atlanta Congenital Defects Program; SGA; Small for gestational age; US; Unite
IgE autoantibodies in bullous pemphigoid: Supporting role, or leading player?
Keywords: اومالیزوماب; Autoantibody; IgE; Eosinophil; Mast cell; Omalizumab
Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma
Keywords: اومالیزوماب; Omalizumab; Allergic asthma; Anti-immunoglobulin E; Asthma control; Exacerbations; Observational study
Long-term efficacy of omalizumab in seven patients with treatment-resistant chronic spontaneous urticaria
Keywords: اومالیزوماب; Chronic spontaneous urticaria; Anti-IgE; Omalizumab
Study of the effect of anti-IgE (omalizumab) on serum level of matrix metalloproteinase-9 as a marker of remodeling in severe asthmatic patients
Keywords: اومالیزوماب; MMP-9, metalloproteinase-9; IgE, immunoglobulin-E; ACT, asthma control test; FEV1, forced expiratory volume in first second; FENO, fraction of exhaled nitric oxideAsthma; Anti-IgE; Omalizumab; Metalloproteinase-9
Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE
Keywords: اومالیزوماب; DTR; dosing table revision; ICS; inhaled corticosteroids; KDapp; apparent equilibrium binding constant; PK-PD; pharmacokinetic and pharmacodynamic; q2w; every 2Â weeks; q4w; every 4Â weeks; sc; subcutaneous; Allergic asthma; Anti-immunoglobulin E; Dosin
Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table
Keywords: اومالیزوماب; Omalizumab; PK/PD; IgE; Bodyweight;
Anti-IgE therapy to Kimura's disease: A pilot study
Keywords: اومالیزوماب; Anti-IgE therapy; Kimura's disease; Eosinophil; Basophil; Omalizumab;
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control
Keywords: اومالیزوماب; Omalizumab; Discontinuation; Asthma control; Duration of treatment; GINA; global initiative for asthma; IgE; immunoglobulin E; FcεRI; high-affinity IgE receptor; BMI; body mass index; FEV1; forced expiratory volume (1 s); ICS; inhaled corticosteroid; OC
Omalizumab management beyond clinical trials: The added value of a network model
Keywords: اومالیزوماب; Omalizumab; Severe allergic asthma; Allergic rhinitis; Asthma comorbidities; Lung function; Treatment discontinuation
Original articleOmalizumab therapy for bullous pemphigoid
Keywords: اومالیزوماب; autoimmunity; bullous pemphigoid; IgE; omalizumab; pruritus; BMZ; basement membrane zone; BP; bullous pemphigoid; BP180; bullous pemphigoid 180 kDa antigen; BP230; bullous pemphigoid 230 kDa antigen; ELISA; enzyme-linked immunosorbent assay; IF; immunoflu
Intérêt d’un traitement par omalizumab dans le cadre d’une immunothérapie spécifique. Recueil d’expérience et analyse de la littérature
Keywords: اومالیزوماب; Omalizumab; Anti-IgE; Immunothérapie spécifique; DésensibilisationOmalizumab; Allergen immunotherapy; Hymenoptera venom allergy; Mite allergy; Asthma
Urticaires inductibles et urticaires chroniques spontanées
Keywords: اومالیزوماب; Urticaire chronique; Urticaire chronique spontanée; Urticaire inductible; Angioedème; Antihistaminiques; Chronic urticarial; Chronic spontaneous urticarial; Inducible urticarial; Angioedema; Antihistamines; Omalizumab;
Therapeutic potential of anti-IL-1β IgY in guinea pigs with allergic asthma induced by ovalbumin
Keywords: اومالیزوماب; AHR; airway hyperresponsiveness; BALF; bronchoalveolar lavage fluid; HE; hematoxylin-eosin; IgE; immunoglobulin E; IgY; immunoglobulin yolk; IL-1β; interleukin-1beta; IL-1ra; IL-1 receptor antagonist; IL-4; interleukin-4; IL-8; interleukin-8; IL-13; inte